MiR-146a-5p inhibits proliferation and promotes apoptosis of oral squamous cell carcinoma cells by regulating NF-κB signaling pathway

OBJECTIVE: The aim of this study was to investigate the function and potential mechanism of micro ribonucleic acid (miR)-146a-5p in oral squamous cell carcinoma (OSCC).

MATERIALS AND METHODS: The expression of miR-146a-5p in OSCC tissues and cell lines was examined by quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) analysis. Then, the role of miR-146a-5p in proliferation was analyzed by Cell Counting Kit-8 (CCK-8) assay. Besides, the proliferation and apoptosis of OSCC cells were detected by the colony formation assay and flow cytometry, respectively. Finally, the regulatory effect of miR-146a-5p/nuclear factor-kappa B subunit 1 (NF-κB1) was determined by Western blotting assay and Luciferase reporter assay system.

RESULTS: The expression of miR-146a-5p was markedly upregulated in OSCC cell lines. In addition, the silence of miR-146a-5p inhibited the proliferation and promoted the apoptosis of OSCC cells. According to the results of the Western blotting analysis and Luciferase reporter gene assay, NF-κB1 was identified as a direct target of miR-146a-5p. Moreover, the downregulation of NF-κB1 restored the inhibitory effect of silenced miR-146a-5p on the proliferation of SCC-9 cells.

CONCLUSIONS: MiR-146a-5p can inhibit the proliferation and accelerate the apoptosis of OSCC cells by directly targeting NF-κB1, and it plays a carcinogenic role in OSCC.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:24

Enthalten in:

European review for medical and pharmacological sciences - 24(2020), 7 vom: 20. Apr., Seite 3717-3723

Sprache:

Englisch

Beteiligte Personen:

Zhu, F-Y [VerfasserIn]
Gan, C-W [VerfasserIn]
Wang, M-X [VerfasserIn]
Sun, B-C [VerfasserIn]
Li, F-J [VerfasserIn]
Qiu, Y-H [VerfasserIn]
Wang, K [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
MIRN146 microRNA, human
MicroRNAs
NF-kappa B

Anmerkungen:

Date Completed 29.03.2021

Date Revised 29.03.2021

published: Print

Citation Status MEDLINE

doi:

10.26355/eurrev_202004_20835

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM309141818